Wondercel Biotech (shenzhen)

This early-phase study tests a new type of universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side ef…

This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have not …

This early-phase study tests a universal (donor-derived) CAR-T cell therapy called UWD-CD19 for people with B-cell lymphoma or leukemia that has not responded to standard treatments. About 30 participants will receive a single infusion of these cells after chemotherapy to see if …

This early-phase study tests a new type of immune cell therapy called universal CAR-T cells in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The therapy targets a protein called GPC3 found on these cancer cells. The main goals are to …

This early-phase study tests a new 'universal' CAR-T cell therapy (UWD-00B) for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses donor cells engineered to target a protein called BCMA on cancer cells. The main goals are to c…